Lopinavir

Author:Prof. Dr. med. Peter Altmeyer

Last updated on: 29.10.2020

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).

Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Virustatic.

Pharmacodynamics (Effect)This section has been translated automatically.

Inhibitor of the HIV-associated protease.

IndicationThis section has been translated automatically.

Combination therapy of HIV infection.

Dosage and method of useThis section has been translated automatically.

Adults and adolescents: 2 times/day 2 tablets (400 mg Lopinavir/100 mg Ritonavir); alternatively 2 times/day 5 ml solution. (juice).
Children > 2 years: according to the manufacturer's technical information.

Undesirable effectsThis section has been translated automatically.

Diarrhea, weakness, fatigue, headache, nausea, pancreatitis, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lipodystrophy syndrome.

Notice! In case of liver diseases, e.g. hepatits B or C, there may be a deterioration of liver function.

InteractionsThis section has been translated automatically.

Interactions are possible with simultaneous use of triazolam, astemizole, pimozide, dihydroergotamine, cisapride, propafenone, terfendadine, flecainide, midazolam, rifampin, St. John's wort.

PreparationsThis section has been translated automatically.

Kaletra (combination with ritonavir)

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer